A Modified Vaccinia Ankara Virus (MVA) Vaccine Expressing African Horse Sickness Virus (AHSV) VP2 Protects Against AHSV Challenge in an IFNAR −/− Mouse Model
2011

MVA Vaccine Protects Mice from African Horse Sickness Virus

Sample size: 12 publication 10 minutes Evidence: high

Author Information

Author(s): Castillo-Olivares Javier, Calvo-Pinilla Eva, Casanova Isabel, Bachanek-Bankowska Katarzyna, Chiam Rachael, Maan Sushila, Nieto Jose Maria, Ortego Javier, Mertens Peter Paul Clement

Primary Institution: Institute for Animal Health, Pirbright, Woking, Surrey, United Kingdom

Hypothesis

Can a modified vaccinia Ankara virus (MVA) vaccine expressing AHSV VP2 protect against AHSV challenge in an IFNAR −/− mouse model?

Conclusion

The MVA-VP2 vaccine provided complete protection against AHSV infection in the mouse model.

Supporting Evidence

  • All vaccinated mice survived the challenge and showed no signs of viraemia.
  • Unvaccinated control mice had a survival rate of only 50% and exhibited severe clinical signs.
  • Statistical analysis indicated significant differences in survival rates between vaccinated and unvaccinated groups.

Takeaway

Researchers tested a vaccine on mice to see if it could protect them from a deadly horse virus, and it worked really well!

Methodology

The study involved infecting IFNAR −/− mice with AHSV-4 and evaluating the protective efficacy of the MVA-VP2 vaccine through clinical signs, survival rates, and virus titres.

Limitations

The study was conducted in a mouse model, which may not fully replicate the response in horses.

Participant Demographics

IFNAR −/− mice were used in the study.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0016503

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication